Remifentanil is a lesser known and used rapid onset / rapid elimination narcotic. Despite the advantage of prompt elimination when the infusion is stopped, this valuable drug has not been aggressively marketed.
Recently, the ownership of Remifentanil has been transferred to Mylan Institutional. With the new ownership has come new marketing to educate anesthesia providers about the safe use of the drug, especially during TIVA procedures.
Click here to go to the Ultiva web site and view their instructional information. If you have experience with this drug, please write a review to share with your colleagues.